PortfoliosLab logoPortfoliosLab logo
FULC vs. BIOX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

FULC vs. BIOX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fulcrum Therapeutics, Inc. (FULC) and Bioceres Crop Solutions Corp. (BIOX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, FULC achieves a -71.53% return, which is significantly lower than BIOX's -64.93% return.


FULC

1D
2.55%
1M
-54.13%
YTD
-71.53%
6M
-64.46%
1Y
-54.23%
3Y*
1.60%
5Y*
-18.10%
10Y*

BIOX

1D
-6.34%
1M
2.87%
YTD
-64.93%
6M
-71.11%
1Y
-90.81%
3Y*
-66.93%
5Y*
-49.68%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

FULC vs. BIOX - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
FULC
Fulcrum Therapeutics, Inc.
-71.53%140.64%-30.37%-7.28%-58.85%51.07%-29.63%23.26%
BIOX
Bioceres Crop Solutions Corp.
-64.93%-78.45%-55.72%14.13%-14.92%128.06%22.80%-16.82%

Correlation

The correlation between FULC and BIOX is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.16

Correlation (3Y)
Calculated over the trailing 3-year period

0.17

Correlation (5Y)
Calculated over the trailing 5-year period

0.15

Correlation (All Time)
Calculated using the full available price history since Jul 19, 2019

0.15

Fundamentals

Market Cap

FULC:

$245.41M

BIOX:

$29.22M

EPS

FULC:

-$1.15

BIOX:

-$3.84

PB Ratio

FULC:

0.74

BIOX:

0.43

Total Revenue (TTM)

FULC:

$0.00

BIOX:

$263.71M

Gross Profit (TTM)

FULC:

$0.00

BIOX:

$97.66M

EBITDA (TTM)

FULC:

-$78.37M

BIOX:

-$1.32M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

FULC vs. BIOX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FULC
FULC Risk / Return Rank: 1616
Overall Rank
FULC Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
FULC Sortino Ratio Rank: 2323
Sortino Ratio Rank
FULC Omega Ratio Rank: 2222
Omega Ratio Rank
FULC Calmar Ratio Rank: 1616
Calmar Ratio Rank
FULC Martin Ratio Rank: 22
Martin Ratio Rank

BIOX
BIOX Risk / Return Rank: 55
Overall Rank
BIOX Sharpe Ratio Rank: 77
Sharpe Ratio Rank
BIOX Sortino Ratio Rank: 11
Sortino Ratio Rank
BIOX Omega Ratio Rank: 22
Omega Ratio Rank
BIOX Calmar Ratio Rank: 22
Calmar Ratio Rank
BIOX Martin Ratio Rank: 1111
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FULC vs. BIOX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and Bioceres Crop Solutions Corp. (BIOX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


FULCBIOXDifference
Sharpe ratioReturn per unit of total volatility

+0.34

Sortino ratioReturn per unit of downside risk

+2.05

Omega ratioGain probability vs. loss probability

0.95

0.73

+0.22

Calmar ratioReturn relative to maximum drawdown

-0.69

-0.98

+0.29

Martin ratioReturn relative to average drawdown

-1.81

-1.30

-0.51

FULC vs. BIOX - Sharpe Ratio Comparison

The current FULC Sharpe Ratio is -0.55, which is higher than the BIOX Sharpe Ratio of -0.89. The chart below compares the historical Sharpe Ratios of FULC and BIOX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


FULCBIOXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.55

-0.89

+0.34

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.16

-0.78

+0.61

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.17

-0.48

+0.31

Drawdowns

FULC vs. BIOX - Drawdown Comparison

The maximum FULC drawdown since its inception was -92.70%, smaller than the maximum BIOX drawdown of -97.68%. Use the drawdown chart below to compare losses from any high point for FULC and BIOX.


Loading charts...

Drawdown Indicators


FULCBIOXDifference

Max Drawdown

Largest peak-to-trough decline

-92.70%

-97.68%

+4.98%

Max Drawdown (1Y)

Largest decline over 1 year

-78.49%

-92.66%

+14.17%

Max Drawdown (3Y)

Largest decline over 3 years

-79.08%

-97.33%

+18.25%

Max Drawdown (5Y)

Largest decline over 5 years

-92.70%

-97.68%

+4.98%

Current Drawdown

Current decline from peak

-89.60%

-97.13%

+7.53%

Average Drawdown

Average peak-to-trough decline

-62.65%

-36.08%

-26.57%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.01%

69.65%

-39.64%

Volatility

FULC vs. BIOX - Volatility Comparison

Fulcrum Therapeutics, Inc. (FULC) has a higher volatility of 73.43% compared to Bioceres Crop Solutions Corp. (BIOX) at 32.05%. This indicates that FULC's price experiences larger fluctuations and is considered to be riskier than BIOX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


FULCBIOXDifference

Volatility (1M)

Calculated over the trailing 1-month period

73.43%

32.05%

+41.38%

Volatility (6M)

Calculated over the trailing 6-month period

95.79%

83.83%

+11.96%

Volatility (1Y)

Calculated over the trailing 1-year period

99.47%

102.46%

-2.99%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

111.24%

64.21%

+47.03%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

111.94%

64.99%

+46.95%

Dividends

FULC vs. BIOX - Dividend Comparison

Neither FULC nor BIOX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

FULC vs. BIOX - Financials Comparison

This section allows you to compare key financial metrics between Fulcrum Therapeutics, Inc. and Bioceres Crop Solutions Corp.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M202220232024202520260
38.20M
(FULC) Total Revenue
(BIOX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


FULC and BIOX have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

FULC has higher volatility (73.43%) compared to BIOX (32.05%). In terms of maximum drawdown, FULC dropped -92.70% vs BIOX's -97.68%.

FULC currently has the higher Sharpe Ratio (-0.55 vs -0.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for FULC and BIOX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer